
Silvia Bozzarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6280548/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology, 2012, 57, 101-107.	1.8	191
2	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Clinical Colorectal Cancer, 2019, 18, 125-132.e2.	1.0	35
3	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1179-1187.	1.2	34
4	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Oncologist, 2013, 18, 379-380.	1.9	34
5	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 2016, 5, 256-264.	1.3	29
6	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiotherapy and Oncology, 2015, 117, 315-321.	0.3	28
7	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist, 2017, 22, 1463-1469.	1.9	27
8	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 2018, 17, e489-e498.	1.0	16
9	Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. Cancers, 2020, 12, 2790.	1.7	15
10	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: AÂPhase II Study. Clinical Colorectal Cancer, 2015, 14, 162-169.	1.0	11
11	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. British Journal of Radiology, 2020, 93, 20190627.	1.0	11
12	Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer. Chemotherapy, 2010, 56, 203-207.	0.8	9
13	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncology, 2019, 15, 4009-4017.	1.1	8
14	Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2019, 11, 788-803.	0.8	8
15	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 2017, 20, 428-437.	2.7	5
16	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 5665.	1.7	5
17	Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. Journal of Personalized Medicine, 2022, 12, 204.	1.1	3
18	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. Expert Opinion on Investigational Drugs. 2022, 31, 425-435.	1.9	3

#	Article	IF	CITATIONS
19	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 2022, 14, 1168.	1.7	о
20	Tumour burden score and immuneâ€related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International, 0, , .	0.2	0